Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06295081
Other study ID # NL79864.091.22
Secondary ID 112927
Status Recruiting
Phase
First received
Last updated
Start date June 15, 2022
Est. completion date July 1, 2044

Study information

Verified date January 2024
Source Radboud University Medical Center
Contact Sylvan Janssen, MSc
Phone +31243613416
Email sylvan.janssen@radboudumc.nl
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational study is to learn about cardiac biomarker release following exercise in amateur athletes. The main questions it aims to answer are: Question 1: What are the reference values for exercise-induced cardiac troponin elevations following walking, cycling and running exercise? Hypothesis 1: We hypothesize that the exercise-induced cTn release is different following walking, cycling and running exercise. Therefore, we will establish reference values for post-exercise cTn concentrations across each of these sport types. Question 2: Is the prevalence of (subclinical) coronary artery disease higher in individuals with high post-exercise cardiac troponin concentrations in comparison to individuals with low post-exercise cardiac troponin concentrations? Hypothesis 2: We hypothesize that athletes with the highest post-exercise cTn concentrations have a higher prevalence of coronary atherosclerosis compared to athletes matched for sex and age with the lowest post-exercise cTn concentrations. Question 3: What is the association between post-exercise cardiac troponin concentrations and major adverse cardiovascular events (MACE) and mortality during long-term follow-up? Hypothesis 3: We hypothesize that post-exercise cTn concentrations beyond the 99th percentile are associated with an increased risk for MACE and mortality during follow-up. This study consists of three phases: Phase 1: two or three visits to the study location for (amongst other measurements) blood draws to assess cardiac troponin concentrations Phase 2: CT scan of the heart in 10% of participants to assess the prevalence of (subclinicial) coronary artery disease. Phase 3: longitudinal follow-up to assess the incidence of major adverse cardiovascular events and mortality during 20-year follow-up. Participants will visit our study centre two, three or four times: Visit 1: baseline measurements including height, weight, body composition and blood pressure will be obtained and a blood sample will be drawn. Visit 2: a blood sample will be drawn and activity data will be obtained from participants' own sports watch or bike computer. Optional visit 3: a blood sample will be drawn. Visit 4: 10% of participants will undergo a cardiac CT scan to assess the prevalence of (subclinical) coronary artery disease.


Description:

For a detailed description, please see the attached study protocol under 'Documents'.


Recruitment information / eligibility

Status Recruiting
Enrollment 1500
Est. completion date July 1, 2044
Est. primary completion date July 1, 2024
Accepts healthy volunteers
Gender All
Age group 40 Years to 70 Years
Eligibility Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Participant of an affiliated mass-participation exercise event with a: - Walking distance =20 km - Cycling distance =100 km - Running distance =15 km - Age: = 40 and <70 years old - Able to understand and perform study related procedures For Phase 2 of the study (i.e. assessment of (sub)clinical coronary artery disease), the following additional criteria are present: • Free from (known) cardiovascular diseases Exclusion Criteria: A potential subject who meets any of the following criteria will be excluded from participation in Phase 2 of the study: - Renal transplantation in the past - Contrast nephropathy in the past - estimated glomerular filtration rate (eGFR) < 30 ml/min - Atrial fibrillation (heart rhythm disorder) - Previous allergic reaction to iodine contrast - Participation in other studies involving radiation - Not willing to be informed about potential incidental findings from the CT-scan

Study Design


Intervention

Other:
Exercise exposure
Exercise is NOT part of our study protocol. Participants will voluntarily participate in a mass-participation exercise event (i.e. walking, cycling or running). Participation in this exercise event is voluntary and independent from participation in this study (i.e. participants would also take part in the exercise event if they did not participate in our study). Therefore, we do not consider the performed exercise an intervention or part of our study protocol. Hence, we consider our study design to be observational. Participants will perform exercise during a mass-participation exercise event, stratified for type of exercise (walking versus running versus cycling; n=500 each). The mass-participation exercise events have a sport-specific minimum distance of: a mass-participation exercise event with a: Walking distance =20 km Cycling distance =100 km Running distance =15 km

Locations

Country Name City State
Netherlands RadboudUMC Nijmegen Gelderland

Sponsors (2)

Lead Sponsor Collaborator
Radboud University Medical Center Maastricht University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other Participant characteristics (personal info) Sex (male/female); name; e-mail address; phone number; place of residence; date of birth (dd-mm-yyyy); mass-participation sports event; distance (km).
If included in the study: Participant identification number (TREAT…).
At day of inclusion
Other Participant characteristics (baseline measurements) Blood pressure: Systolic and diastolic blood pressure (mmHg) at rest; heart rate at rest (bpm).
Anthropometry: Height (cm); weight (kg); BMI (kg/m2); body fat percentage (%); fat-free mass (kg ).
BMI: body mass index;
At day of inclusion
Other Participant characteristics (Exercise characteristics): Exercise type (walking/cycling/running); exercise distance (km); start and finish time (hh:mm); pause time (hh:mm); exercise duration (hh:mm); average speed (km/h); average speed (min/km); average heart rate (bpm).
If used a sports watch or bike computer: .FIT-file or .CSV-file of activity.
Visit 2 (within 6 hours post-exercise cessation)
Other Medical History questionnaire, part 1 (general info and cardiovascular complaints) General: level of education (primary education/preparatory vocational education/secondary vocational education/university of applied sciences/university bachelor/university master/PhD/other); ethnicity (Caucasian(European)/Afro-American/Asian/mixed/other); smoking (yes/no but I used to smoke/never); alcohol consumption (units/week); frequency of being active for =30 minutes (days/week); ever used performance-enhancing substances (yes/no, if yes: which substances).
Cardiovascular complaints and/or procedures: cardiovascular complaints [e.g. dyspnoea, chest pain, fainting, palpitations] (yes/no); ever had coronary stenting or coronary artery bypass grafting (yes/no, if yes: reason of procedure, year and hospital where procedure was performed).
Within 1 week following inclusion
Other Medical History questionnaire, part 2 (diseases and/or conditions) Diseases and/or conditions (all yes/no, if yes, date of diagnosis (dd-mm-yyyy)): atherosclerosis; stroke/TIA/CVA; atrial fibrillation; COPD/lung diseases; embolism [anywhere other than lungs]; erectile disorders; intermittent claudication; myocardial fibrosis; fainting; conduction disorders; heart attack/myocardial infarction; heart failure; heart rhythm disorder; heart murmur; hypertrophic cardiomyopathy; lung embolism; kidney failure or kidney disorders; myocarditis; angina/chest pain; rheumatic disorders; diabetes mellitus; thrombosis; vascular dementia; hypertension; hypercholesterolaemia; hypotension; narrowed/occluded artery; dilation of artery [aneurysm], disease of lymph nodes or vessels, other diseases (yes/no, if yes: which disease and date of diagnosis (mm-yyyy). Within 1 week following inclusion
Other Medical History questionnaire, part 3 (family history, COVID-19 info and medication use) Family history of cardiovascular diseases in 1st-degree family members before age 60 years: sudden death <50 years (yes/no); myocardial infarction or cardiac arrest (yes/no); coronary stenting or coronary artery bypass grafting (yes/no); stroke [cerebral infarction or haemorrhage] (yes/no); high cholesterol (yes/no); dilation of an artery [aneurysm] (yes/no); narrowing of an artery [stenosis] (yes/no, if yes: which artery (carotid/coronary/legs/other).
COVID-19: had coronavirus infection (yes/no/probably, if yes or probably: date of infection (dd-mm-yyyy) and how the infection was diagnosed (PCR test/CT scan/antigen test/self-test/general practitioner or medical specialist diagnosed/I only have a suspicion that I had a coronavirus infection).
Medication use: participant uses medication regularly in the last year (yes/no, if yes: name of drug, dose (mg), frequency (doses/day), comments) Other: room for further comments regarding health in general
Within 1 week following inclusion
Other Exercise History questionnaire, part 1 (exercise history, participation in endurance races and current training status) Lifetime exercise history (if multiple sports: the following data will be collected per sport discipline): sport discipline; age started (years); age quit (years); frequency (days/week); frequency (months/year); average duration of a session (minutes).
Participation in endurance races (how often participated in the following races/events): Zevenheuvelenloop (n); half marathon (n); marathon (n); ultra marathon (n); Nijmegen Four Days Marches (n); Kennedy march [80 km] (n); cycling events =120 km (n); Alpe d'HuZes (n); triathlon sprint (n); triathlon quart or half (n); triathlon whole/Ironman (n); other endurance races.
Current endurance activities (if multiple sports: the following data will be collected per sport discipline): sport discipline; age started (years); age quit (years); frequency (days/week); frequency (months/year); average duration of a session (minutes).
Within 1 week following inclusion
Other Exercise History questionnaire, part 2 (strength exercise) Strength: participation in strength training (yes/no).
If yes: frequency (days/week) of strength training, further specified as:
Per type of muscle-strengthening exercise (using weight machines/bodyweight exercises/resistance exercises/holistic exercises): frequency (days/week); duration (0/<10/10-20/21-30/31-40/41-50/51-60/>60 minutes); muscle groups trained (legs/hips/back/abdomen/chest/shoulders/arms). Intensity at which the abovementioned muscle-strengthening exercises will be performed (0-10, 0 being extremely light, 10 being extremely heavy).
Other: room for further comments regarding exercise history
Within 1 week following inclusion
Other Other biomarker concentrations in blood creatinine (µmol/L); eGFR (ml/min/1.73m2); total cholesterol (mmol/L), HDL cholesterol (mmol/L), LDL cholesterol (mmol/L), albumin (g/L), cardiac myosin binding protein C (ng/ml).
eGFR: estimated glomerular filtration rate; HDL: high-density lipoprotein; LDL: low-density lipoprotein;
At day of inclusion
Primary High-sensitivity cardiac troponin I (hs-cTnI) Concentrations of high-sensitivity cardiac troponin I (hs-cTnI) in plasma in ng/L Within 5 days before exercise event, within 6 hours post-exercise cessation, 24-48 hours post-exercise cessation
Primary High-sensitivity cardiac troponin T (hs-cTnT) Concentrations of high-sensitivity cardiac troponin T (hs-cTnT) in plasma in ng/L Within 5 days before exercise event, within 6 hours post-exercise cessation, 24-48 hours post-exercise cessation
Secondary General CT scan data CT scan date (dd-mm-yyyy); average heart rate during scan (bpm); total radiation dose (mSv); beta-blockers administration (yes/no, if yes: dose (mg)); nitro-glycerine administration (yes/no, if yes: dose (mg)); image quality (good/moderate/poor); FFR series obtained (yes/no, if yes: quality(good/moderate/poor)); incidental findings. within 3 months after inclusion
Secondary Coronary artery calcification score Coronary artery calcium score [=CACS], per coronary artery or other (LM/LAD/LCX/RCA/RI/Aorta/Valves/Other) and total: lesion count (n); Agatston score (AU); volume (mm3); density (HU). Total CACS (AU); total volume (mm3); total density (HU); MESA percentile (%).
LM: left main; LAD: left anterior descending; LCX: left circumflex; RCA: right coronary artery; RI: ramus intermedius; AU: Agatston units; HU: Hounsfield units; MESA: Multi-Ethnic Study of Atherosclerosis.
within 3 months after inclusion
Secondary Coronary stenosis and plaque characteristics Coronary stenoses, per segment (1-18): maximum stenosis degree (0%/1-24%/25-49%/50-69%/70-99%/100%/non-diagnostic/vessel absent); number of calcified plaques (n); number of partially calcified plaques (n); number of non-calcified plaques (n).
Presence of myocardial bridging (yes/no); heart 'dominance' (PDA supplied by RCA/PDA supplied by LCX); room for general comments on CT scan.
In general, not per segment: stenosis involvement score (n); stenosis severity score (n); plaque burden (P0/P1/P2/P3/P4); high-risk plaque features, per type [low attenuation plaque/positive remodelling/spotty calcification/napkin ring sign] (yes/no); modifiers, per modifier [non-diagnostic/having =high-risk plaque features/ischemia/exceptions including coronary artery dissection, anomalous origin of the coronary arteries, coronary artery (pseudo) aneurysm, vasculitis, coronary artery fistula, extrinsic coronary artery compression, arterio-venous malformation, other causes] (yes/no); CAD-RADS 2.0 score.
within 3 months after inclusion
Secondary Computed tomography derived Fractional Flow Reserve CT-derived FFR per coronary artery (LM/LAD/LCX/RCA): FFR at the beginning of vessel (ratio); FFR at 1.5 mm diameter of vessel or most distal evaluable part (ratio); FFR at 20 mm distal from stenosis (ratio).
FFR signs for ischemia present [=FFR=0.75] (yes/no); borderline ischemia [=FFR 0.76-0.80] (yes/no), non-ischemia [=FFR >0.80] (yes/no).
FFR: fractional flow reserve
within 3 months after inclusion
Secondary Incidence of mortality Incidence of mortality (yes/no), if yes: date of death (dd-mm-yyyy) and cause of death; cardiovascular death (yes/no). 5 years after inclusion, 10 years after inclusion, 15 years after inclusion, 20 years after inclusion. Time-to-event: From the date of inclusion until the date of first documented date of death (from any cause), assessed up to 20 years after inclusion
Secondary Incidence of major adverse cardiovascular events Incidence of MACE (yes/no), if yes: date, type of event (myocardial infarction/stroke/heart failure/revascularisation (both acute and elective)/sudden cardiac arrest), hospitalization (yes/no).
MACE: major adverse cardiovascular events.
At 1/2/3/4/5/6/7/8/9/10/11/12/13/14/15/16/17/18/19/20 years after inclusion.Time-to-event: From the date of inclusion until the date of first documented major adverse cardiovascular event, assessed up to 20 years after inclusion.
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A